Real-world data backs Kymriah’s safety profile, says NovartisWith more competition looming for its CAR-T therapy Kymriah, Novartis has pointed to new data that show the Share XReal-world data backs Kymriah’s safety profile, says Novartishttps://pharmaphorum.com/news/real-world-data-backs-kymriahs-safety-profile-says-novartis/
Early data from Roche’s NHL drug mosunetuzumab steals the show at ASHThere’s been a slew of scientific data coming from the American Society for Hematology (ASH) conference, but promising Share XEarly data from Roche’s NHL drug mosunetuzumab steals the show at ASHhttps://pharmaphorum.com/news/early-data-from-roches-mosunetuzumab-steals-the-show-at-ash/
Celgene bags FDA okay for Revlimid combo in lymphomaCelgene has added another new indication for its blood cancer blockbuster Revlimid, with the FDA approving its use Share XCelgene bags FDA okay for Revlimid combo in lymphomahttps://pharmaphorum.com/news/celgene-bags-fda-okay-for-revlimid-combo-in-lymphoma/
EU approves Kyowa Kirin’s drug for rare lymphomaThe European Commission has approved Poteligeo (mogamulizumab), a treatment for rare types of non-Hodgkin’s lymphoma. The drug is Share XEU approves Kyowa Kirin’s drug for rare lymphomahttps://pharmaphorum.com/news/eu-approves-kyowa-kirins-drug-for-rare-lymphoma/
Celltrion/Teva Rituxan biosimilar edges closer to US approvalIt looks increasingly likely that Roche’s cancer blockbuster Rituxan (rituximab) will face competition from a cheaper biosimilar in Share XCelltrion/Teva Rituxan biosimilar edges closer to US approvalhttps://pharmaphorum.com/news/celltrion-teva-rituxan-biosimilar-edges-closer-to-us-approval/
Great news for Kite after CAR-T success in cancer patientsKite looks all set for a regulatory approval later this year for its CAR-T drug KTE-CI9 after the Share XGreat news for Kite after CAR-T success in cancer patientshttps://pharmaphorum.com/news/good-news-kites-car-t-drug-lymphoma/
